GLP-1 Months 2–6: The Titration Phase

Month 1 was the adjustment period. Months 2 through 6 are where the real transformation happens — and where the clinical management of your treatment matters most. This is the titration phase: your dose increases at regular intervals, your weight loss accelerates, and your body goes through changes that require ongoing medical attention.

The Standard Titration Schedules

Both semaglutide and tirzepatide follow a stepped dose-escalation protocol. Your dose increases every 4 weeks, assuming you're tolerating the current level:

Semaglutide (Wegovy / Compounded)

The standard FDA-approved titration for weight management:

• Weeks 1–4: 0.25 mg weekly (starting dose — sub-therapeutic)
• Weeks 5–8: 0.5 mg weekly
• Weeks 9–12: 1.0 mg weekly
• Weeks 13–16: 1.7 mg weekly
• Week 17+: 2.4 mg weekly (maintenance dose)

Many patients find their optimal therapeutic response between 1.0 mg and 2.4 mg. Not everyone needs or tolerates the full 2.4 mg dose — finding your effective dose is the point of titration.

Tirzepatide (Zepbound / Mounjaro / Compounded)

Tirzepatide's dual GIP/GLP-1 mechanism uses higher milligram doses but follows the same 4-week escalation:

• Weeks 1–4: 2.5 mg weekly (starting dose)
• Weeks 5–8: 5 mg weekly
• Weeks 9–12: 7.5 mg weekly
• Weeks 13–16: 10 mg weekly
• Weeks 17–20: 12.5 mg weekly
• Week 21+: 15 mg weekly (maximum dose)

The SURMOUNT-5 head-to-head trial showed tirzepatide produced an average of about 20.2% total body weight loss over 72 weeks, compared with approximately 13.7% for semaglutide — though individual responses vary significantly.

Month-by-Month: What to Expect

Month 2 (Dose 2)

This is when most patients notice their first significant weight loss acceleration. Moving from the starting dose to the second tier often produces a noticeable jump in appetite suppression. Some patients experience a return of GI side effects similar to (but usually milder than) the first week — nausea, slight bloating, and changes in bowel habits for a few days after each dose increase.

Typical weight loss through month 2: 5–10 pounds cumulative.

Month 3 (Dose 3)

The third dose level is often where patients start seeing clinically meaningful changes. Clothes fit differently, energy levels improve as excess weight comes off, and metabolic markers (blood sugar, blood pressure) may start improving. Your provider should check in on side effects and may order labs around this time.

Typical weight loss through month 3: 8–15 pounds cumulative.

Months 4–5 (Dose 4–5)

This is the peak dose-escalation period. You're approaching therapeutic doses, and weight loss is accelerating. This is also when some patients hit their first plateau — a period where the scale stalls despite compliance. Plateaus are normal and typically break within 2–4 weeks as the body adjusts to its new set point.

Typical weight loss through month 5: 12–25 pounds cumulative (varies widely).

Month 6 (Maintenance Dose or Near It)

By month 6, most patients are at or near their target dose. The rate of weight loss may start to moderate — this is expected. Your body is reaching a new equilibrium. Your provider should order comprehensive labs at this point and discuss your long-term treatment plan.

Typical weight loss through month 6: 15–35 pounds cumulative (highly individual).

When Your Provider Should Hold or Slow Titration

Not everyone follows the textbook schedule, and that's fine. Your provider may keep you at a dose longer or even reduce your dose if:

• GI side effects are severe: Persistent vomiting, inability to eat, or significant dehydration are reasons to pause at the current dose or step back
• You're losing weight too rapidly: Weight loss exceeding 1% of body weight per week sustained over several weeks increases the risk of gallstones, muscle loss, and nutritional deficiencies
• Lab results warrant caution: Worsening kidney function, elevated liver enzymes, or concerning thyroid markers may call for a dose adjustment
• You're happy at the current dose: If you're achieving good weight loss and tolerating a mid-range dose well, there's no requirement to push to the maximum. The goal is the lowest effective dose

Managing Plateaus

Weight loss plateaus during titration are common and usually temporary. Before assuming the medication has stopped working:

• Check your protein intake: Inadequate protein accelerates muscle loss, which slows metabolism. Aim for at least 1 gram per kilogram of your ideal body weight daily.
• Add resistance exercise: Weight training preserves lean mass and can break through plateaus. Even two sessions per week makes a measurable difference.
• Reassess hydration: Dehydration can cause water retention that masks fat loss on the scale.
• Be patient: A 2–3 week plateau after a dose increase is normal. Your body is recalibrating. If the plateau extends beyond 4–6 weeks at a therapeutic dose, discuss with your provider.

What Your Provider Should Be Monitoring

During the titration phase, responsible clinical oversight includes:

• Check-ins at each dose increase to assess tolerance
• Lab work at month 3 and month 6 (at minimum): kidney function, liver enzymes, A1c, thyroid panel
• Blood pressure monitoring — many patients need blood pressure medication adjustments as they lose weight
• Assessment for gallbladder symptoms, especially with rapid weight loss
• Mental health check-ins — mood changes can occur during significant body transformation

The Big Picture

The titration phase isn't a race to the highest dose. It's a carefully managed process of finding the dose that gives you meaningful weight loss with manageable side effects. Some patients reach their goals at mid-range doses. Others need the maximum. Both outcomes are valid, and both require a provider who's paying attention to your individual response — not running a one-size-fits-all protocol.